Oncotarget

Immunology and Microbiology

The popularity and success of Oncotarget has prompted us to launch the Immunology and Microbiology section.

The Immunology and Microbiology section publishes papers in all areas of basic and clinical research (mostly unrelated to cancer research), including: innate and adaptive immunity, immune cell development, antigen recognition and responses, inflammation, cytokines, signal transduction, gene regulation, cell proliferation, autoimmunity, infectious disease, microbiology, allergy, hypersensitivities, transplantation, clinical immunology, immunotherapy, vaccines, mucosal immunology, methods and more.

Submission is centralized via the Oncotarget submission system. Please choose the Immunology section to direct your manuscript to the Section Editor. Instructions to authors are common for all sections of Oncotarget. Your paper will be published in Oncotarget within the Immunology section.

There are several advantages of the Immunology section of Oncotarget compared with related journals:

  • High impact factor, 6.63.
  • Ultra-rapid publication within a few days of acceptance.
  • Papers rejected by leading journals can be submitted with the original reviews and rebuttal. An editorial decision will be made in 1-4 days.
  • Papers may also be communicated by members of the Section Editorial/Advisory Board.

Section Editorial Board includes the most prominent scientists in the field.

  • Frederick W. Alt
    Harvard Medical School, Boston, MA
  • Sebastien Amigorena
    Institut Curie, Paris, France
  • Dan Barouch
    Harvard Medical School, Boston, MA, USA
  • Jeffrey A. Bluestone
    University of California, San Francisco, CA, USA
  • Xuetao Cao
    Chinese Academy of Medical Sciences, Beijing, China
  • Max D. Cooper
    Emory University, Atlanta, GA, USA
  • Chen Dong
    Tsinghua University, Beijing, China
  • Daniel Douek
    NIAID/NIH, Bethesda, MD, USA
  • Douglas T. Fearon
    Cold Spring Harbor Laboratory, NY, USA
  • Richard A. Flavell
    Yale University, New Haven, CT, USA
  • Dmitry I. Gabrilovich
    Wistar Institute, Philadelphia, PA, USA
  • Ken J. Ishii
    Osaka University, Osaka, Japan
  • Yoichiro Iwakura
    Tokyo University of Science, Chiba, Japan
  • Tsuneyasu Kaisho
    Wakayama Medical University, Wakayama, Japan
  • Tadamitsu Kishimoto
    Osaka University, Osaka, Japan
  • Vijay K Kuchroo
    Harvard Medical School, Boston, MA USA
  • Ruslan M. Medzhitov
    Yale University, New Haven, CT, USA
  • Stefan A. Muljo
    NIAID/NIH, Bethesda, MD, USA
  • André Nussenzweig
    NCI/NIH, Bethesda, MD, USA
  • Klaus Rajewsky
    The Max Delbrück Center, Berlin, Germany
  • Caetano Reis e Sousa
    The Francis Crick Institute, London, UK
  • Alexander Rudensky
    Memorial Sloan-Kettering Cancer Center, NY, USA
  • Padmanee Sharma
    M. D. Anderson Cancer Center, Houston, TX, USA
  • Hong-Bing Shu
    Wuhan University, Wuhan, China
  • Leonidas Stamatatos
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
  • Hendrik G. Stunnenberg
    Radboud University Nijmegen, The Netherlands
  • Kiyoshi Takeda
    Osaka University, Osaka, Japan
  • Osamu Takeuchi
    Kyoto University, Japan
  • Zhigang Tian
    Chinese Academy of Sciences, Hefei, China
  • Jon J. van Rood
    Europdonor Foundation, Leiden, The Netherlands 
  • Peter K. Vogt, Ph.D.
    The Scripps Research Institute, La Jolla, CA


Copyright © 2017 Impact Journals
Impact Journals is a registered trademark of Impact Journals, LLC